The shared roles of IFI27+ cells and BC-AS2 in inflammation, immune regulation, and ECM remodeling suggest that therapeutic strategies aiming to downregulate pro-inflammatory factors or block certain collagen degradation pathways might yield more effective anti-aging outcomes. Here, IFI27 is linked to breast cancer.